Mizushima et al., in their fairly recent review article, have concluded that AR inactivation holds promise not only as a potential therapeutic strategy for ovarian cancer but also as a method for enhancing chemosensitivity, especially in patients with AR-positive tumors [68]. This evidence concerns the gene AR and ovarian carcinoma.